Search results | drug delivery

Reports

Targeted Drug Delivery Partnering

Targeted Drug Delivery Partnering 2009-2014 report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.

Topical Drug Delivery Partnering

Topical Drug Delivery Partnering 2009-2014 report provides understanding and access to the topical drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.

Transdermal Drug Delivery Partnering

Transdermal Drug Delivery Partnering 2009-2014 report provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.

Injectable Drug Delivery Partnering

Injectable Drug Delivery Partnering 2009-2014 report provides understanding and access to the injectable drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

Drug Delivery Partnering Terms and Agreements in Pharma and Biotech

The Drug Delivery Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the drug delivery partnering agreements entered into by the worlds leading companies.

Cancer Vaccine Partnering Agreements

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies

Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics

The Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

Insights

Drug delivery

Drug delivery is the method or process of administering a drug to achieve a therapeutic effect

Industry analysis in drug delivery partnering activity

Industry analysis reveals that over 2000 drug delivery partnering deals have been announced between January 2009 and April 2014, showing that drug delivery partnering is in good health, with numerous big pharma and big biotech companies actively partnering delivery technologies to support development of targeted therapeutics

Bio news: QLT seeks to dispose of drug delivery business

QLT has retained Goldman Sachs to explore the sale or spin-out of QLT’s Punctal Plug Delivery System (PPDS) and to determine whether the company should retain or explore opportunities to partner or sell its Visudyne business

Alkermes buys up Elan Drug Delivery Technology Unit for $960 million

Alkermes has agreed to buy Elan Drug Technologies, the drug delivery unit of Elan Corporation, in a deal valued at $960 million.

Orphan diseases partnering: A lucrative step for drug makers

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

Antibody-drug conjugates

Antibody-drug conjugates (ADCs) are a new type of targeted therapy, used for example for cancer

Fresenius: Hospital, i.v. drugs and acquisition experts

Fresenius is a large pharmaceutical company developing pharmaceutical products and medical devices for critically care and chronically ill patients. ‘Caring for life’ is the motto behind the company’s worldwide success and commitment to patient care.

Claris the next acquisition target for injectable drug makers?

Hot on the heals of the acquisition of Strides Arcolab by Mylan, investors are speculating whether Claris Lifesciences may be next

Current Agreements Deal Analysis Update : December 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in November 2014 and give you an exclusive opportunity to gain discounted annual subscription access to our database.

Nektar Therapeutics – Well respected partner of choice

Nektar Therapeutics is a leading biopharma company developing clinical stage products based upon its advanced polymer conjugate chemistry technology.

Events

Sorry, your search returned no results.


Deals

Collaboration agreement for DEP dendrimer drug delivery technology

Starpharma has signed a second, expanded agreement with AstraZeneca in the field of cancer medicine using Starpharma’s proprietary DEP dendrimer drug delivery technology.

Unilife pharma alliances with Novartis for drug delivery systems

Unilife announced pharma alliances with Novartis, big pharma company

Labcyte biopharma partners with AstraZeneca to advance drug delivery

Labcyte biopharma partners with AstraZeneca, a big pharma company, to use acoustic dispensing combined with mass spectrometry to greatly advance drug discovery applications

Sanofi pharma deals Unilife for injectable drug delivery systems

Unilife announced the signing of a long-term supply contract with Sanofi after pharma deals with the big pharma company.

Avanir wins pharmaceutical licensing deal for OptiNose novel breath powered intranasal migraine drug delivery system

Avanir Pharmaceuticals and OptiNose have entered pharmaceutical licensing deals for an exclusive North American license of OptiNose migraine treatment.

Novo Nordisk pair up with Caisson Biotech in drug delivery biotech partnering

Caisson Biotech has entered into a biotech partnering, development and license agreement with Novo Nordisk

Grant award to advance a dermal treatment based on dendrimer drug delivery technology

GSK was awarded a grant to advance a dermal treatment based on Starpharma’s dendrimer drug delivery technology.

pSivida forges $169m Pfizer pact for eye drug delivery program

Drug delivery company pSivida has announced it amended and restated its Research and Development Agreement with Pfizer to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma.

Collaborative R&D agreement for implantable drug delivery system

Collaboration to research and develop a new approach to treating Parkinson’s disease that involves delivering a potential new medicine to the brain using an implantable drug delivery system

Bayer partners with NPERC on drug delivery

Bayer Schering Pharma signed an agreement to conduct joint research on a biodegradable injection drug delivery system with the National Pharmaceutical Engineering Research Center.